These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27633250)

  • 1. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
    Sturm S; Forsberg A; Nave S; Stenkrona P; Seneca N; Varrone A; Comley RA; Fazio P; Jamois C; Nakao R; Ejduk Z; Al-Tawil N; Akenine U; Halldin C; Andreasen N; Ricci B
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):382-391. PubMed ID: 27633250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
    Borroni E; Bohrmann B; Grueninger F; Prinssen E; Nave S; Loetscher H; Chinta SJ; Rajagopalan S; Rane A; Siddiqui A; Ellenbroek B; Messer J; Pähler A; Andersen JK; Wyler R; Cesura AM
    J Pharmacol Exp Ther; 2017 Sep; 362(3):413-423. PubMed ID: 28642233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).
    Nave S; Doody RS; Boada M; Grimmer T; Savola JM; Delmar P; Pauly-Evers M; Nikolcheva T; Czech C; Borroni E; Ricci B; Dukart J; Mannino M; Carey T; Moran E; Gilaberte I; Muelhardt NM; Gerlach I; Santarelli L; Ostrowitzki S; Fontoura P
    J Alzheimers Dis; 2017; 58(4):1217-1228. PubMed ID: 28550255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
    Hirvonen J; Kailajärvi M; Haltia T; Koskimies S; Någren K; Virsu P; Oikonen V; Sipilä H; Ruokoniemi P; Virtanen K; Scheinin M; Rinne JO
    Clin Pharmacol Ther; 2009 May; 85(5):506-12. PubMed ID: 19129751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase B inhibitor, selegiline, reduces
    Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P
    Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
    Gulyás B; Pavlova E; Kása P; Gulya K; Bakota L; Várszegi S; Keller E; Horváth MC; Nag S; Hermecz I; Magyar K; Halldin C
    Neurochem Int; 2011 Jan; 58(1):60-8. PubMed ID: 21075154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
    Freedman NM; Mishani E; Krausz Y; Weininger J; Lester H; Blaugrund E; Ehrlich D; Chisin R
    J Nucl Med; 2005 Oct; 46(10):1618-24. PubMed ID: 16204711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Clinical Application of Positron Emission Tomography Imaging Agents for Monoamine Oxidase B.
    Meyer JH; Braga J
    Front Neurosci; 2021; 15():773404. PubMed ID: 35280341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.
    Bench CJ; Price GW; Lammertsma AA; Cremer JC; Luthra SK; Turton D; Dolan RJ; Kettler R; Dingemanse J; Da Prada M
    Eur J Clin Pharmacol; 1991; 40(2):169-73. PubMed ID: 1906004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
    Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
    Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.
    Fowler JS; Logan J; Azzaro AJ; Fielding RM; Zhu W; Poshusta AK; Burch D; Brand B; Free J; Asgharnejad M; Wang GJ; Telang F; Hubbard B; Jayne M; King P; Carter P; Carter S; Xu Y; Shea C; Muench L; Alexoff D; Shumay E; Schueller M; Warner D; Apelskog-Torres K
    Neuropsychopharmacology; 2010 Feb; 35(3):623-31. PubMed ID: 19890267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B).
    Nag S; Lehmann L; Kettschau G; Toth M; Heinrich T; Thiele A; Varrone A; Halldin C
    Bioorg Med Chem; 2013 Nov; 21(21):6634-41. PubMed ID: 24012376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.
    Lemoine L; Gillberg PG; Svedberg M; Stepanov V; Jia Z; Huang J; Nag S; Tian H; Ghetti B; Okamura N; Higuchi M; Halldin C; Nordberg A
    Alzheimers Res Ther; 2017 Dec; 9(1):96. PubMed ID: 29229003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
    Fowler JS; Logan J; Volkow ND; Shumay E; McCall-Perez F; Jayne M; Wang GJ; Alexoff DL; Apelskog-Torres K; Hubbard B; Carter P; King P; Fahn S; Gilmor M; Telang F; Shea C; Xu Y; Muench L
    Neuropsychopharmacology; 2015 Feb; 40(3):650-7. PubMed ID: 25249059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
    Thomas T
    Neurobiol Aging; 2000; 21(2):343-8. PubMed ID: 10867219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.
    Sacher J; Houle S; Parkes J; Rusjan P; Sagrati S; Wilson AA; Meyer JH
    J Psychiatry Neurosci; 2011 Nov; 36(6):375-82. PubMed ID: 21463543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
    Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.
    Murugan NA; Chiotis K; Rodriguez-Vieitez E; Lemoine L; Ågren H; Nordberg A
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1369-1382. PubMed ID: 30919054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
    Kumar B; Dwivedi AR; Sarkar B; Gupta SK; Krishnamurthy S; Mantha AK; Parkash J; Kumar V
    ACS Chem Neurosci; 2019 Jan; 10(1):252-265. PubMed ID: 30296051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.